Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - April 20, 2026 319 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMN24 IsKia study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Ex-NFL Player Pays For 500 Mammograms To Honor Late Mom Who... October 22, 2019 Registered Dietitian vs. Nutritionist March 3, 2021 Neoadjuvant Chemoimmunotherapy Superior to Neoadjuvant Chemotherapy with Event-Free Survival Benefit in... April 10, 2024 FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma April 5, 2022 Load more HOT NEWS The Potential of AI to Improve Cancer Care is Only Going... ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO... Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer Study Finds Shortcomings in Monitoring Caregivers’ Emotional Health
